Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

Perlara PBC Announces Pharma Collaboration with Novartis

Perlara PBC Announces Pharma Collaboration with Novartis SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/ Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment […]

Read more

Amgen Incubators Grow Startup for Harvest

Amgen Incubators Grow Startup for Harvest Venture division seeks access to technology, potential takeovers. San Fernando Valley Business Journal, July 11-24, 2016 By STEPHANIE HENKEL, Staff Reporter Amgen inc. hopes to get in on more ground floors by sponsoring startups in the biotech hubs in Cambridge, Mass. and, more recently, in San Francisco. The Thousand Oaks biopharmaceutical company last month […]

Read more

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies Kite to License Cell Design Labs’ Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs’ Reversible ‘On/Off Switch’ Technology Provides Dynamic Range of Control to Precisely Regulate Activity of Engineered CAR […]

Read more

Cell Design Labs Executes Series of Private Financings

Cell Design Labs Executes Series of Private Financings New Company Focused on Discovering and Developing Next-Generation Immunotherapies for Cancer and Other Complex Diseases   SAN FRANCISCO, Calif. June 2, 2016 — Cell Design Labs, Inc. today announced it has executed a staged series of investor and strategic partner financings totaling $34.4 million to fund the company’s start-up operations. The investors, […]

Read more

Avant Completes Acquisitions of Amarantus, Theranostics Health

Avant Completes Acquisitions of Amarantus and Theranostics Health Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health. In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus’ research-use-only assays for multiple sclerosis and […]

Read more

ViewPoint Therapeutics Raises $4 Million in Series A Financing

ViewPoint Therapeutics Raises $4 Million in Series A Financing ViewPoint Therapeutics, Inc., a privately-held biotechnology company pioneering the development of crystallin stabilizers to prevent and treat cataracts and presbyopia, today announced the closing of a $4 million Series A financing. The transaction was co-led by Mission Bay Capital and Lagunita BioSciences LLC. Also included in the syndicate was healthcare-dedicated investor, […]

Read more

Miroculus Acquires Microfluidics Firm Kapplex

MicroRNA Diagnostics Developer Miroculus Acquires Microfluidics Firm Kapplex Miroculus, a San Francisco startup developing microRNA-based diagnostic tests, said Monday that it has acquired Toronto-based microfluidics firm Kapplex for an undisclosed amount. Miroculus emerged from stealth mode earlier this year at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference. It aims to tap into the growing evidence that miRNAs can serve as useful […]

Read more

Dow AgroSciences and TeselaGen to collaborate

A new collaboration between Dow AgroSciences and TeselaGen Biotechnology Inc. is designed to produce a biological design automation platform that can speed up discovery work for new agricultural products. “TeselaGen has created a powerful suite of tools for DNA design,” said Daniel R. Kittle, Ph.D., vice president, research and development, Dow AgroSciences. “These tools have the potential to accelerate our […]

Read more

Perlstein Lab continues their rare disease drug discovery

Perlstein Lab, or PLab as it is also known, continues to hone its automated drug discovery platform and presents its latest iteration Wednesday March 23rd at Y Combinator Demo Day. The platform they created helps the bio startup focus on finding cures for rare diseases rather than common ones. This novel approach is different from most Big Pharma labs and […]

Read more
Page 3 of 812345...Last »

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter